Your browser doesn't support javascript.
loading
Post-transplant lymphoproliferative disorder in adult renal transplant recipients: survival and prognosis.
Morton, Muir; Coupes, Beatrice; Ritchie, James; Roberts, Stephen A; Klapper, Paul E; Byers, Richard J; Vallely, Pamela J; Ryan, Kate; Picton, Michael L.
Afiliação
  • Morton M; a Department of Renal Medicine , Central Manchester University Hospitals Foundation Trust , Manchester , UK.
  • Coupes B; a Department of Renal Medicine , Central Manchester University Hospitals Foundation Trust , Manchester , UK.
  • Ritchie J; b Center for Epidemiology, Institute of Population Health, Salford Royal NHS Foundation Trust , Salford , UK.
  • Roberts SA; c Centre for Biostatistics, Institute of Population Health, University of Manchester , Manchester , UK.
  • Klapper PE; d Department of Clinical Virology , Central Manchester University Hospitals Foundation Trust , Manchester , UK.
  • Byers RJ; e Microbiology and Virology Unit, School of Translational Medicine, the University of Manchester, Manchester Academic Health Sciences Centre , Manchester , UK.
  • Vallely PJ; f Department of Histopathology , Central Manchester University Hospitals Foundation Trust , Manchester , UK.
  • Ryan K; g School of Cancer and Enabling Sciences, Faculty of Medical and Human Sciences, University of Manchester , Manchester , UK.
  • Picton ML; h Manchester Academic Health Science Centre , Manchester , UK.
Leuk Lymphoma ; 57(2): 299-305, 2016 Feb.
Article em En | MEDLINE | ID: mdl-25976109
ABSTRACT
Post-transplant lymphoproliferative disorder (PTLD) is a rare, serious complication following solid organ transplantation, with an incidence of 2.6 cases per 1000 patient years. Optimal treatment strategies and risk stratifications specific to kidney transplantation are lacking and PTLD mortality remains high. This study investigated survival and prognosis in 89 cases of PTLD presenting over 44 years at Manchester Royal Infirmary. Patient survival following diagnosis was 72% at 6 months, 67% at 1 year and 54% at 3 years. In multivariate analysis, a poorer 3 year survival was associated with acute kidney injury at diagnosis (p = 0.0001), impaired renal function (p = 0.04), early onset (p = 0.02), T cell disease (p = 0.02) and previous treatment with anti-thymocyte globulin (p = 0.04). The inclusion of graft function adds prognostic value to risk stratification and should be explored further. Strategies to improve survival should include timing and choice of immuno-chemotherapy, preparation for dialysis and aggressive surveillance for sepsis and treatment toxicity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Leuk Lymphoma Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Leuk Lymphoma Ano de publicação: 2016 Tipo de documento: Article